37. Generalised pustular psoriasis Clinical trials / Disease details
Clinical trials : 79 / Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004021-33-GB (EUCTR) | 04/05/2018 | 20/12/2017 | To Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis | A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis - ANB019-002 - Generalized Pustular Psoriasis | Generalized Pustular Psoriasis (GPP) MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Psoriasis pustular;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody Other descriptive name: Alvarez 2 | AnaptysBio Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Phase 2 | United States;United Kingdom |